

In the claims:

Please amend the claims as follows:

1-7. **(Canceled)**

8. **(Currently amended)** A preparation composition comprising at least 70% biologically active receptor-immunoglobulin fusion protein (receptor-Ig-fusion protein), obtained by culturing a mammalian host cell transformed with DNA encoding the receptor-Ig fusion protein in a culture system having a temperature of about 27° C to about 35° C, wherein the receptor-Ig fusion protein comprises a member of the TNF family of receptors.

9. **(Canceled)**

10. **(Currently amended)** The preparation composition of claim 8, wherein the receptor-Ig-fusion protein comprises lymphotoxin- β receptor (LT- β -R)-Ig fusion protein.

11. **(Currently amended)** The preparation composition of claim 8, wherein the receptor-Ig-fusion protein comprises herpes virus entry mediator (HVEM)-Ig-fusion protein.

12-15. **(Canceled)**

16. **(Currently amended)** A pharmaceutical preparation obtained by

- (a) culturing a host cell transformed with DNA encoding a lymphotoxin- β receptor (LT- β -R)- receptor-Ig-fusion protein in a culture system having a temperature of about 27° C to about 32 ° C, ~~wherein the receptor-Ig fusion protein comprises a member of the TNF family of receptors~~, thereby expressing biologically active ~~receptor~~ LT- β -R-Ig-fusion proteins;
- (b) recovering biologically active ~~receptor~~ LT- β -R-Ig-fusion proteins from said culture system; and

- (c) combining the biologically active ~~receptor~~ LT- β -R-Ig-fusion proteins of step (b) with a pharmaceutically acceptable carrier.

17-25. (Canceled)

26. (Currently amended) A preparation ~~composition~~ comprising a biologically active receptor-Ig-fusion protein obtained by culturing yeast transformed with DNA encoding the receptor-Ig-fusion protein in a culture system having a temperature of about 10° C to about 25° C, wherein the receptor-Ig fusion protein comprises a member of the TNF family of receptors.

27. (Cancel)

28. (Currently amended) The preparation ~~receptor-Ig-fusion protein~~ of claim 26 ~~27~~ comprising wherein the receptor-Ig-fusion protein comprises LT- β -R-Ig-fusion protein.

29. (Currently amended) The preparation ~~receptor-Ig-fusion protein~~ of claim 26 ~~27~~, comprising wherein the receptor-Ig-fusion protein comprises HVEM-Ig-fusion protein.

30-36. (Canceled)

37. (Currently amended) A preparation ~~composition~~ comprising at least 70% biologically active HVEM-Ig-fusion proteins obtained by culturing a mammalian host cell transformed with DNA encoding the HVEM-Ig-fusion protein in a culture system having a temperature of about 27° C to about 35 ° C.

38. (Currently amended) The preparation ~~composition~~ of claim 37, wherein the culture system has a temperature of about 27° C to about 32 ° C.

39. (Currently amended) The preparation ~~composition~~ of any one of claims 8, 10, and 11, wherein the culture system has a temperature of about 27° C to about 32 ° C.

40. **(New)** The preparation of claim 8 or 10, wherein the host cell is a Chinese hamster ovary (CHO) cell or a COS cell.
41. **(New)** The preparation of claim 16, wherein the host cell is a CHO cell or a COS cell.
42. **(New)** The preparation of claim 8 or 10, wherein the preparation is a cell culture supernatant.